Replies to post #310741 on Avid Bioservices Inc (CDMO)

[biopharm]

All biotechs until partnered can be played with

All BPs have the same issues of patient deaths due to the treatment and it is all just becoming more well known NOW due to scientific evidence as NOW we know what the protein pathways should be like in a good immune response vs bad vs no response at all

Even Daiich Sankyo that bought up Ambit (PS Targeting collaboration...)

Daiichi Sankyo's ambition to build a pipeline of new oncology drugs may have just taken another big hit. The Japanese drugmaker has been forced to stop recruiting patients into a late-stage trial of pexidartinib after "serious liver toxicity" was seen in two patients.
http://www.fiercepharma.com/pharma-asia/daiichi-suspends-enrolment-rare-tumor-trial-after-two-patients-develop-liver-side

At that time Daiichi Sankyo brings Antoine over from Astra Zeneca that knew of PS Targeting
https://www.linkedin.com/in/antoine-yver-51950113

All we know now is even SOC for Immunotherapy drugs still only about 20% effective and BPs need a platform drug to increase patient responders and more importantly ....provide safety and reduce all the off target TOXICITIES

Dr Jedd Wolchok just coming out with that....and wonder who is looking to add some of their top execs to the Peregrine BOD

I hope it is Exosomes first deal and then more leverage for future deals